Novel influenza A (H1N1) is a new flu virus of swine origin that was first detected in Mexico and the United States in March and April, 2009. The first novel H1N1 patient in the United States was confirmed by laboratory testing at CDC on April 15, 2009. The second patient was confirmed on April 17, 2009. It was quickly determined that the virus was spreading from person-to-person. On April 22, CDC activated its Emergency Operations Center to better coordinate the public health response. On April 26, 2009, the United States Government declared a public health emergency.
It’s thought that novel influenza A (H1N1) flu spreads in the same way that regular seasonal influenza viruses spread; mainly through the coughs and sneezes of people who are sick with the virus.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that it has been selected by the Beijing Centers for Disease Control and Prevention (Beijing CDC) as one of the five manufacturers to supply seasonal influenza vaccine to the citizens of Beijing.
Sinovac Biotech Ltd., a leading provider of biopharmaceutical products in China, announced today that Sinovac Biotech (Hong Kong) Ltd., its wholly owned subsidiary company in Hong Kong, has received the Certificate of Drug/Product Registration from the Hong Kong Department of Health for its seasonal influenza vaccine Anflu.
The 2009/2010 Influenza A (H1N1) is one of several viruses responsible for respiratory-related infections. A new study from Rhode Island Hospital examined patients with viruses and found distinguishing characteristics of the H1N1 virus in how it affects respiratory illness. Their findings will be presented at the annual meeting of the Infectious Diseases Society of America to be held in Vancouver, Canada on Friday, Oct. 22.
A variant of last year's pandemic influenza linked to fatal cases carried a mutation that enabled it to infect a different subset of cells lining the airway, according to new research. The study, due to be published next week in the Journal of Virology, suggests that the mutant virus could have impaired the lungs' ability to clear out germs.
Kentucky-based Union Springs Pharmaceuticals announced today an agreement with BIOSAFE® of Pittsburgh to market products containing the patented and novel antimicrobial polymer, HM4100. Similar to its flagship product, MyClyns (antimicrobial germ spray), Union Springs Pharmaceuticals will identify the products as MyClyns Antimicrobial Surface Treatments and will be the first company to bring these unique products to the market.
BioCryst Pharmaceuticals, Inc. announced the presentation of data related to intravenous (i.v.) peramivir for the treatment of influenza at the 48th Annual Infectious Diseases Society of America (IDSA) meeting being held in Vancouver, Canada.
CEL-SCI Corporation announced today it has received approval from seven hospital Institutional Review Boards in India to begin enrollment of subjects for a Phase III clinical trial of Multikine, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer.
Having an egg allergy is not a reason to avoid getting the 2010-2011 flu vaccination.
NanoViricides, Inc. announced today that the Company President was invited to and presented a talk at the Second Annual Conference of the American Society for NanoMedicine (ASNM).
Bioniche Life Sciences Inc. a research-based, technology driven Canadian biopharmaceutical company, today announced that two of its senior research scientists gave presentations at the Modern Vaccine and Adjuvant Formulation Conference in Cannes, France this week.
The Organization of Teratology Information Specialists (OTIS), a non-profit organization based at the University of California, San Diego with affiliates across North America, urges pregnant women to receive the influenza vaccine as soon as possible. The recommendation comes shortly after the American College of Obstetricians and Gynecologists Committee on Obstetric Practice issued new guidelines regarding the influenza vaccine during pregnancy.
You're having that dreaded feeling. Your muscles are aching, you've got a a fever and sore throat . Get ready: It is flu season again! The flu is a respiratory virus that's contagious. In addition to the symptoms above, a, cough and headache, as well as diarrhea may indicate the virus is present.
NanoViricides, Inc. reports that it has filed its financial year end annual report (Form 10K) with the Securities and Exchange Commission (SEC) yesterday in a timely manner.
A new Consumer Reports Health poll reveals a disconcerting proportion of "at risk" groups who will not get the flu vaccine this year. Of most concern, only 40% of Americans in the "work risk" category—meaning those who care for young children and those who work in residential nursing homes, hospitals, and other health care environments—said they would definitely get the vaccine this year, which combines the seasonal and the 2009 H1N1 (swine) flus, while 28% said they would definitely not get the vaccine.
Inovio Pharmaceuticals, Inc., a leader in the development of therapeutic and preventive vaccines against cancers and infectious diseases, announced today that a scientific paper demonstrating strong and protective immune responses from candidate SynCon™ DNA vaccines in preclinical studies using Inovio's intradermal (ID) DNA delivery technology was one of the top cited scientific articles in the past three years in the journal Vaccine.
CEL-SCI Corporation announced today it has received approval from the first Taiwanese Institutional Review Board ("IRB") to begin enrollment of subjects for a Phase III clinical trial of Multikine®, the Company's flagship immunotherapy developed as a first-line standard of care in treating head and neck cancer. An IRB is a group formally designated by an institution to review and monitor research involving human subjects and to ensure protection of their rights and welfare.
The best way to prevent the spread of the flu to patients in a medical setting would be to require all health-care workers to get an annual flu shot, says the American Academy of Pediatrics.
Sanofi Pasteur, the vaccines division of the sanofi-aventis Group, has been awarded a three-year contract for $56.94 million by the U.S. Department of Health and Human Services (HHS) to maintain flocks to enable manufacturing pandemic influenza vaccine at full capacity on a year-round basis.
Flu activity in the Southern Hemisphere, where the flu season is ending, has been 'typical,' the federal Centers for Disease Control and Prevention said Thursday. All three types of flu that normally circulate are present, although the H1N1 'swine flu' strain that caused last year's pandemic has replaced the seasonal H1N1 strain that circulated before 2009.
With the influenza vaccine already available and more supply anticipated than ever before, the National Foundation for Infectious Diseases convened ten of the country's leading medical and public health groups to call on all Americans to get vaccinated this season.
Terms
While we only use edited and approved content for Azthena
answers, it may on occasions provide incorrect responses.
Please confirm any data provided with the related suppliers or
authors. We do not provide medical advice, if you search for
medical information you must always consult a medical
professional before acting on any information provided.
Your questions, but not your email details will be shared with
OpenAI and retained for 30 days in accordance with their
privacy principles.
Please do not ask questions that use sensitive or confidential
information.
Read the full Terms & Conditions.